Afghanistan vs Gabon: Average cost of multi drug-resistant tuberculosis treatment
Afghanistan
1,000 constant 2022 US$
in 2024
Gabon
995 constant 2022 US$
in 2024
Afghanistan rank
48th
Gabon rank
50th
Average cost of multi drug-resistant tuberculosis treatment over time
- Afghanistan
- Gabon
How they compare
Afghanistan currently reports 1,000 constant 2022 US$ against 995 constant 2022 US$ in Gabon, a difference of 5 constant 2022 US$.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Afghanistan ahead.
Afghanistan ranks 48th and Gabon ranks 50th of 92 countries.
Across the 2 decades both report, Afghanistan averaged higher in 1 and Gabon in 1.
Head to head by decade
| Decade | Afghanistan | Gabon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,250 constant 2022 US$ | 643.5 constant 2022 US$ | 606.5 constant 2022 US$ | Afghanistan |
| 2020s | 1,000 constant 2022 US$ | 1,112 constant 2022 US$ | 112.4 constant 2022 US$ | Gabon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Afghanistan or Gabon?
- Afghanistan, at 1,000 constant 2022 US$ against 995 constant 2022 US$ in Gabon as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Afghanistan and Gabon?
- 5 constant 2022 US$, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Gabon?
- 7 years are reported by both, from 2018 to 2024.
- How do Afghanistan and Gabon rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Afghanistan ranks 48th and Gabon ranks 50th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.